- Home
- JNVR vs CNSP Comparison
JNVR vs CNSP Comparison
Compare JNVR & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNVR
- CNSP
- Stock Information
- Founded
- JNVR 2018
- CNSP 2017
- Country
- JNVR United States
- CNSP United States
- Employees
- JNVR N/A
- CNSP N/A
- Industry
- JNVR Finance: Consumer Services
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- JNVR Finance
- CNSP Health Care
- Exchange
- JNVR Nasdaq
- CNSP Nasdaq
- Market Cap
- JNVR 7.3M
- CNSP 6.5M
- IPO Year
- JNVR 2023
- CNSP 2019
- Fundamental
- Price
- JNVR $5.29
- CNSP $0.09
- Analyst Decision
- JNVR
- CNSP Strong Buy
- Analyst Count
- JNVR 0
- CNSP 1
- Target Price
- JNVR N/A
- CNSP $0.50
- AVG Volume (30 Days)
- JNVR 18.8K
- CNSP 12.2M
- Earning Date
- JNVR 03-27-2025
- CNSP 03-31-2025
- Dividend Yield
- JNVR N/A
- CNSP N/A
- EPS Growth
- JNVR N/A
- CNSP N/A
- EPS
- JNVR N/A
- CNSP N/A
- Revenue
- JNVR $1,820,969.00
- CNSP N/A
- Revenue This Year
- JNVR N/A
- CNSP N/A
- Revenue Next Year
- JNVR N/A
- CNSP N/A
- P/E Ratio
- JNVR N/A
- CNSP N/A
- Revenue Growth
- JNVR N/A
- CNSP N/A
- 52 Week Low
- JNVR $3.37
- CNSP $0.08
- 52 Week High
- JNVR $11.84
- CNSP $23.90
- Technical
- Relative Strength Index (RSI)
- JNVR 49.60
- CNSP 37.39
- Support Level
- JNVR $4.88
- CNSP $0.09
- Resistance Level
- JNVR $5.61
- CNSP $0.10
- Average True Range (ATR)
- JNVR 0.63
- CNSP 0.01
- MACD
- JNVR -0.03
- CNSP -0.00
- Stochastic Oscillator
- JNVR 24.18
- CNSP 26.90
About JNVR Janover Inc.
Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from transaction fees.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.